C-suite barometer: life sciences & pharmaceuticals sector view
Featuring commentary from our Forvis Mazars experts and contributors including Damien Catoir, Servier, and Cédric Moreau, Sofinnova Partners, the report provides a valuable benchmark for sector players looking to navigate a rapidly evolving landscape.
Key findings
- 96% report growth, with a clear majority also boasting growing revenues, eleven points higher than others globally.
- 55% of C-suite executives cite increased competition and 47% cite supply chain restrictions as the top factors holding back growth.
- 39% of leaders identify economic factors as having the biggest impact on businesses, with 37% viewing the emergence of technologies as significant.
- 67% of firms in the sector are boosting investment, averaged across all business activities
Looking ahead, executives have outlined three core strategic priorities for 2025 and beyond: entering new products and services, accelerating digital transformation to enhance efficiency and agility, international expansion, and strengthening supply chains in response to geopolitical and climate risks- particularly sustainability and supplier responsibility- into core business strategy.
Explore the full findings and discover how sector leaders are preparing for growth in a complex and competitive environment.
